INTUITUS
12.10.2016 09:09:49 CEST | Business Wire | Press release
The MD of one of Europe’s leading private equity advisers has warned that technology and IT ‘red flags’ could put at risk the exits or re-financings of companies that would otherwise be seeing deals get over the line successfully with international and London-based institutions and corporate investors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161012005052/en/
While various reports have indicated a surge of interest from foreign investors in UK private-equity-owned assets during the second half of 2016 - partly driven by a sharp drop in the value of the pound - that shows signs of continuing into 2017, forward planning in the twelve months leading up to the exit can have a huge impact not only on deal value but whether the deal concludes.
Fixing technology and IT operations can require considerable time and effort, warns Intuitus MD and founder, Calum Stewart:
“Technology has never been more critical to exit readiness than it is today and our client base consistently tells us that if IT problems are discovered in the lead-up to exit it is often too late to redress the situation before potential buyers start taking a look. Potential issues and deal-breakers include intellectual property disputes, contractual disputes, capacity planning and product development problems.”
“In a typical sale process, any significant technology or IT problem presenting a current or future risk will be likely to delay the process and may also depreciate the value that you’re trying to extract. In the worst instance, it could even derail the sale completely.”
- Intuitus - whose private equity clients include Inflexion, The Carlyle Group, Dunedin, Triton and Scottish Equity Partners - is in on track to advise on over 100 deals during 2016, with approximately 30% of deal activity involving non-UK assets.
- Intuitus offers its private equity and corporate clients commercially-focused, independent technology and IT expertise throughout the full investment life cycle - at the point of acquisition, during ownership and at exit. Supported by a network of internationally-experienced consultants, mainly former CEOs, CTOs, CIOs and IT Directors from a wide range of industry sectors, and managed through the company’s unique, integrated delivery model, the company is targeting expansion in the UK, Benelux, France, Germany and the Nordics in 2017.
- Intuitus won the Specialist Adviser of the Year award at The Private Equity Awards 2016.
Follow Intuitus on LinkedIn and Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005052/en/
Contact:
Intuitus
Calum Stewart
+44 (0)131 618 0512
or
Freer
Consultancy
Nick Freer
+44 (0)7841 571 871
nick@freerconsultancy.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom